The underlying causes of Alzheimer's disease
are not fully understood, but a good deal of evidence points to the
accumulation of β-amyloid, a protein that's toxic to nerve cells.
β-amyloid is formed by the activity of several enzymes, including one
called BACE1. Most Alzheimer's disease patients have elevated levels of
BACE1, which in turn leads to more brain-damaging β-amyloid protein. In a
paper published in The Journal of Neuroscience, researchers at
Sanford-Burnham Medical Research Institute (Sanford-Burnham) found that
BACE1 does more than just help produce β-amyloid - it also regulates
another cellular process that contributes to memory loss. This means
that just inhibiting BACE1's enzymatic activity as a means to prevent or
treat Alzheimer's disease isn't enough - researchers will have to
prevent cells from making it at all.
"Memory loss is a big problem - not just in Alzheimer's disease, but
also in the normal aging population," said Huaxi Xu, Ph.D., professor in
Sanford-Burnham's Del E. Webb Neuroscience, Aging, and Stem Cell
Research Center and senior author of the study. "In this study, we
wanted to better understand how BACE1 plays a role in memory loss, apart
from β-amyloid production."
To do this, Xu and his team used a mouse model that produces human
BACE1. Mice produce a different type of β-amyloid, one that's far less
toxic than the human version. So, in this system, they could look solely
at how BACE1 functions independent from β-amyloid formation. If BACE1
only acted to produce β-amyloid, the researchers would expect to see no
effect when mice produce human BACE1 - since mouse β-amyloid isn't very
toxic, extra BACE1 would be no big deal. Instead, they saw that the
enzyme still impaired learning and memory, indicating a secondary
function at work.
If it's not producing β-amyloid, what is BACE1 doing? Many years ago,
scientists found that a protein in the brain - protein kinase A (PKA),
better known for directing cellular metabolism - also plays an important
role in memory formation. In this study, Xu and colleagues found that
BACE1 disrupts the cell's production of other molecules required for PKA
function. By that mechanism, BACE1 inactivates PKA and therefore
inhibits memory formation in mice, even in the absence of neurotoxic
β-amyloid.
"So BACE1 is a double whammy when it comes to memory," Xu said. "But
that also means that a therapy that targets BACE1 could be a double
punch against Alzheimer's disease, and even just normal aging-related
memory loss. That's why we're now looking for ways to block BACE1
expression in the brain."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment